CD274 and neoplasm: The study revealed that durvalumab at 20 mg/kg Q4W in combination with tremelimumab at 1 mg/kg Q4W exhibited manageable tolerability and anti-tumor activity, regardless of PD-L1 expression, laying the groundwork for dosing in Phase III studies.